Literature DB >> 8581287

Endothelium-dependent relaxations mediated by inducible B1 and constitutive B2 kinin receptors in the bovine isolated coronary artery.

G R Drummond1, T M Cocks.   

Abstract

1. Rings of bovine left anterior descending coronary artery (LAD) were contracted with the thromboxane A2-mimetic, U46619 (1-30 nM), to approximately 40% of their maximum contraction to 125 mM KCl Krebs solution (KPSSmax) for comparison of responses to the B1 and B2 kinin receptor agonists, des-Arg9-bradykinin (des-Arg9-BK) and bradykinin (BK), respectively. Relaxation responses were normalized as percentages of the initial U46619-induced contraction level, while contractile responses were expressed as percentages of KPSSmax. 2. After 6 h of in vitro incubation in Krebs solution at 37 degrees C, des-Arg9-BK (pEC50, 8.00 +/- 0.08; maximum response (Rmax), 93.9 +/- 1.9%) and BK (pEC50, 9.75 +/- 0.07; Rmax, 100.1 +/- 0.7%) caused endothelium-dependent relaxations in precontracted rings of bovine LAD which were competitively and selectively antagonized by the B1 receptor antagonist, des-Arg9-[Leu8]-BK (pA2, 6.27 +/- 0.11) and the B2 receptor antagonist Hoc-140 (pA2, 9.63 +/- 0.14), respectively. 3. At 3 h of in vitro incubation, the sensitivity (pEC50, 7.45 +/- 0.10) and Rmax (84.6 +/- 3.3%) to des-Arg9-BK were significantly less than those obtained in the same tissues at 6 h (pEC50, 7.94 +/- 0.06; Rmax, 91.4 +/- 2.5%), whereas endothelium-dependent relaxations to BK and ACh were unaffected by incubation time. 4. Relaxation responses to des-ARg9-BK, but not BK, at both 3 h and 6 h were significantly attenuated by the protein synthesis inhibitors, cycloheximide (30 and 100 microM) and actinomycin D (2 microM). 5. At 6 h, the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine (L-NOARG, 100 microM), caused a significant 2 fold decrease in pEC50 (9.58 +/- 0.03) but had no effect on Rmax for BK. For des-Arg9-BK, L-NOARG (100 microM) caused a marked and significant decrease in both the pEC50 and Rmax and revealed contractions to low concentrations of des-Arg9-BK. In both cases, L-NOARG inhibition was reversed in the presence of L-arginine (10 mM). 6. At 6 h removal of the endothelium abolished relaxation responses to des-Arg9-BK and BK, and for des-Arg9-BK, but not BK, unmasked concentration-dependent contractions (pEC50, 7.57 +/- 0.09; Rmax, 83.4 +/- 9.1%). The sensitivity of contractions to des-Arg9-BK increased slightly from 3 h (pEC50, 7.37 +/- 0.08) to 6 h (pEC50, 7.62 +/- 0.12) of in vitro incubation; however, there was a small but significant depression in the maximum response over this time (Rmax, 126.8 +/- 8.5% and 103.3 +/- 8.6% for 3 h and 6 h of incubation respectively). 7. In conclusion, the bovine LAD contains inducible B1 and constitutive B2 endothelial cell kinin receptors, both of which mediate endothelium-dependent relaxation partly via the release of NO. B1 receptors were also present on the smooth muscle layer of the bovine LAD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8581287      PMCID: PMC1909050          DOI: 10.1111/j.1476-5381.1995.tb15098.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  41 in total

Review 1.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

2.  The ability of des-Arg9-bradykinin to relax rabbit isolated mesenteric arteries is acquired during in vitro incubation.

Authors:  D Deblois; F Marceau
Journal:  Eur J Pharmacol       Date:  1987-10-06       Impact factor: 4.432

3.  Pharmacological modulation of the up-regulated responses to des-Arg9-bradykinin in vivo and in vitro.

Authors:  D deBlois; J Bouthillier; F Marceau
Journal:  Immunopharmacology       Date:  1989 May-Jun

4.  Expression cloning of a rat B2 bradykinin receptor.

Authors:  A E McEachern; E R Shelton; S Bhakta; R Obernolte; C Bach; P Zuppan; J Fujisaki; R W Aldrich; K Jarnagin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

5.  Inhibition of endothelium-dependent vasorelaxation by arginine analogues: a pharmacological analysis of agonist and tissue dependence.

Authors:  G R Martin; M L Bolofo; H Giles
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

6.  Differential pharmacology of cloned human and mouse B2 bradykinin receptors.

Authors:  J F Hess; J A Borkowski; T Macneil; G Y Stonesifer; J Fraher; C D Strader; R W Ransom
Journal:  Mol Pharmacol       Date:  1994-01       Impact factor: 4.436

7.  Effects of bradykinin in the rat isolated perfused heart: role of kinin receptors and endothelium-derived relaxing factor.

Authors:  A R Baydoun; B Woodward
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

8.  Kinin receptors mediating the effects of bradykinin on the coronary circulation in anaesthetized greyhounds.

Authors:  J Staszewska-Woolley; O L Woodman
Journal:  Eur J Pharmacol       Date:  1991-04-10       Impact factor: 4.432

9.  L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro.

Authors:  P K Moore; O A al-Swayeh; N W Chong; R A Evans; A Gibson
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

10.  Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors.

Authors:  J V Mombouli; S Illiano; T Nagao; T Scott-Burden; P M Vanhoutte
Journal:  Circ Res       Date:  1992-07       Impact factor: 17.367

View more
  12 in total

1.  Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors.

Authors:  J B Pesquero; R C Araujo; P A Heppenstall; C L Stucky; J A Silva; T Walther; S M Oliveira; J L Pesquero; A C Paiva; J B Calixto; G R Lewin; M Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice.

Authors:  Masao Kakoki; Kelli A Sullivan; Carey Backus; John M Hayes; Sang Su Oh; Kunjie Hua; Adil M H Gasim; Hirofumi Tomita; Ruriko Grant; Sarah B Nossov; Hyung-Suk Kim; J Charles Jennette; Eva L Feldman; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

3.  Tissue engineering of a collagen-based vascular media: Demonstration of functionality.

Authors:  Stacey C Schutte; Zhenzhen Chen; Kelvin G M Brockbank; Robert M Nerem
Journal:  Organogenesis       Date:  2010 Oct-Dec       Impact factor: 2.500

4.  Protease-activated receptor-2 turnover stimulated independently of receptor activation in porcine coronary endothelial cells.

Authors:  J R Hamilton; J M Chow; T M Cocks
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin-induced coronary vasodilation.

Authors:  P G McLean; M Perretti; A Ahluwalia
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  B2 kinin receptor activation is the predominant mechanism by which trypsin mediates endothelium-dependent relaxation in bovine coronary arteries.

Authors:  Grant R Drummond; Stavros Selemidis; Thomas M Cocks
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

7.  Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury.

Authors:  Masao Kakoki; Robert W McGarrah; Hyung-Suk Kim; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

8.  Haemodynamic and cardiac effects of kinin B1 and B2 receptor stimulation in conscious instrumented dogs.

Authors:  P Bélichard; B Loillier; J L Paquet; J M Luccarini; D Pruneau
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

Review 9.  The kallikrein-kinin system in health and in diseases of the kidney.

Authors:  Masao Kakoki; Oliver Smithies
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

Review 10.  The kallikrein-kinin system in diabetic nephropathy.

Authors:  Hirofumi Tomita; Ryan B Sanford; Oliver Smithies; Masao Kakoki
Journal:  Kidney Int       Date:  2012-02-08       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.